Promising Survival Results for Ivonescimab Over Pembrolizumab in NSCLC Treatment at WCLC 2026

Positive Survival Outcomes from HARMONi-2 Study at WCLC 2026

The latest data presented by Akeso, Inc. at the 2026 World Conference on Lung Cancer (WCLC) highlighted the significant survival benefits observed in patients receiving Ivonescimab, compared to those treated with Pembrolizumab for PD-L1-positive non-small cell lung cancer (NSCLC). This landmark data stems from the randomized, double-blind Phase III study called HARMONi-2, focusing on patients who are in need of effective first-line treatment options.

Key Findings of the HARMONi-2 Study

Conducted at multiple centers, this study involved detailed analysis involving patients diagnosed with locally advanced or metastatic NSCLC. As of the last updated data cut-off date on August 20, 2026, the results yielded promising figures, showcasing Ivonescimab's ability to prolong overall survival. The findings were presented by Professor Caicun Zhou, who serves as the Principal Investigator and is also the President of the International Association for the Study of Lung Cancer (IASLC).

Overall Survival Rates

The intention-to-treat (ITT) population showed that patients treated with Ivonescimab had a median overall survival of 30.8 months, while those on Pembrolizumab experienced a median survival of just 22.6 months. This remarkable survival difference marked a 27% reduction in the risk of death, thus reinforcing Ivonescimab's potential as a more effective first-line treatment.

Long-Term Survival Advantage

Interestingly, the survival advantage offered by Ivonescimab extends over time. Two-year overall survival rates stood at 57.9% for the Ivonescimab group against 48.0% for their Pembrolizumab counterparts. Further extending to three years, the survival rates dropped to 45.0% compared to 33.1%. Such data indicates a compelling long-term survival advantage that could shift treatment paradigms in this area.

Minimal Risks in High-Risk Patients

A noteworthy aspect of the HARMONi-2 study was its examination of squamous NSCLC patients, representing 45.5% of the participants. Traditionally, these patients are seen as high risk for anti-VEGF treatments. Nevertheless, no significant increase in bleeding risk was found in patients treated with Ivonescimab, addressing previous concerns associated with anti-VEGF therapies among individuals with central tumors or those encasing major vessels.

Efficacy Across Different PD-L1 Levels

The study analyzed the efficacy of Ivonescimab across varying PD-L1 expression levels. Specifically, in the PD-L1 TPS ≥50% subgroup, patients receiving Ivonescimab did not reach the median OS, showcasing a substantial benefit compared to the 23.2 months seen with Pembrolizumab. This indicates that Ivonescimab could have transformative implications not just broadly, but also for more specific subsets of lung cancer patients.

Broad Safety Profile

In terms of safety, Ivonescimab exhibited a favorable overall safety profile, with no new adverse signals reported. The results indicated that the safety characteristics were consistent between Ivonescimab and Pembrolizumab, providing reassurance about its use in clinical settings.

Future Directions for Akeso

Akeso's study sets a promising pathway forward, particularly as they pursue further research through the ongoing international Phase III trial HARMONi-7, which continues to evaluate Ivonescimab in similar patient populations. Moreover, the study's findings may encourage additional exploration into treatment options targeting other areas beyond lung cancer. With advancements in research and development technologies, Akeso aims to position itself at the forefront of biopharmaceutical innovation, continuously striving to deliver better healthcare solutions.

Conclusion

The data emerging from the HARMONi-2 study communicates a compelling narrative regarding the effectiveness of Ivonescimab over Pembrolizumab in the treatment of PD-L1-positive NSCLC. The superior survival rates, combined with a favorable safety profile, suggest that Ivonescimab could not only redefine first-line treatment protocols but also enhance the quality of life for many patients battling this formidable disease.